Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vivani Medical ( (VANI) ) has shared an announcement.
On September 17, 2025, Vivani Medical announced the record date for the spin-off of its subsidiary, Cortigent, Inc., set for October 8, 2025. Cortigent specializes in brain implant devices with neuromodulation technology and is expected to trade on the Nasdaq under the symbol ‘CRGT’. This strategic move aims to allow both Vivani and Cortigent to focus on their respective areas, with Vivani concentrating on drug implants for metabolic diseases and Cortigent advancing its neurostimulation technology. The spin-off is anticipated to enhance operational flexibility and provide direct investment opportunities in Cortigent’s pioneering technologies, positioning it among the few public companies in the neuromodulation and brain-computer interface sector.
The most recent analyst rating on (VANI) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vivani Medical stock, see the VANI Stock Forecast page.
Spark’s Take on VANI Stock
According to Spark, TipRanks’ AI Analyst, VANI is a Neutral.
Vivani Medical’s overall score reflects its challenging financial situation and unfavorable valuation. Despite some positive corporate events and neutral technical indicators, the company’s consistent losses and reliance on external financing weigh heavily on the score. The strategic focus on core drug implant business and recent milestones offer some potential for improvement, but substantial operational and financial efficiency improvements are necessary for a stronger outlook.
To see Spark’s full report on VANI stock, click here.
More about Vivani Medical
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that develops miniature, ultra long-acting drug implants using its proprietary NanoPortal™ platform. The company’s focus is on creating GLP-1 based implants for metabolic diseases such as obesity and type 2 diabetes, aiming to improve medication adherence and patient tolerance.
Average Trading Volume: 127,904
Technical Sentiment Signal: Strong Sell
Current Market Cap: $75.24M
For detailed information about VANI stock, go to TipRanks’ Stock Analysis page.